Presentation is loading. Please wait.

Presentation is loading. Please wait.

Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes.

Published byHertha Althaus Modified over 5 years ago

Similar presentations

Presentation on theme: "Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes."— Presentation transcript:

1 Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes remission at 48 weeks and those not in remission at 48 weeks (solid square: remission; open circle... Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes remission at 48 weeks and those not in remission at 48 weeks (solid square: remission; open circle: non-remission). ALT, alanine aminotransferase; AUCglucagon, area-under-the-glucagon-curve; BMI, body mass index; ISSI-2, Insulin Secretion-Sensitivity Index-2; pre-IIT, prior to intensive insulin therapy; post-IIT, after intensive insulin therapy; p values are for differences between groups. Caroline K Kramer et al. BMJ Open Diab Res Care 2016;4:e000270 ©2016 by American Diabetes Association

Download ppt "Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes."

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type  2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.

Plasma active glucagon-like peptide-1 (GLP-1) response in patients with type  2 diabetes during the liquid high-fat meal test at baseline, 12 weeks and.
Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.

Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Effect of Ma-Pi diet versus control diet on change in TNF-α, IL-6, CRP, BAP test, and IGF-1. Effect of Ma-Pi diet versus control diet on change in TNF-α,

Effect of Ma-Pi diet versus control diet on change in TNF-α, IL-6, CRP, BAP test, and IGF-1. Effect of Ma-Pi diet versus control diet on change in TNF-α,
Illustration of the causal inference scheme.

Illustration of the causal inference scheme.
Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,
Functional characteristics of neutrophils prior to and following (phorbol myristate acetate) PMA stimulation. Functional characteristics of neutrophils.

Functional characteristics of neutrophils prior to and following (phorbol myristate acetate) PMA stimulation. Functional characteristics of neutrophils.
(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.
Visceral fat area (VFA, cm2), subcutaneous fat area (SFA, cm2), body mass index (BMI, kg/m2) and waist circumference (WC, cm) levels according to the quartiles.

Visceral fat area (VFA, cm2), subcutaneous fat area (SFA, cm2), body mass index (BMI, kg/m2) and waist circumference (WC, cm) levels according to the quartiles.
Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.

Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Similar presentations

Ads by Google